{"entity":{"id":"immuneel","kind":"company","name":"Immuneel Therapeutics","aka":[],"tldr":"A Bengaluru cell therapy company that brought Barcelona's academic CD19 CAR-T to India as Qartemi, the country's second approved CAR-T, after the IMAGINE trial.","summary":"Immuneel Therapeutics is a private cell and gene therapy company based at Narayana Health City in Bengaluru, formed to make CAR-T therapy affordable and accessible in India. Its lead product, varnimcabtagene autoleucel (IMN-003A, brand Qartemi), is the Indian version of ARI-0001, the academic CD19 CAR-T developed at Hospital Clinic de Barcelona and approved in Spain under the hospital exemption. Immuneel ran IMAGINE, the first industry-sponsored CAR-T trial in India, a phase 2 study in relapsed or refractory B-cell malignancies reported at ASH 2023 and in Hematological Oncology, and Qartemi received CDSCO market authorisation for relapsed or refractory B-cell lymphoma in 2024. The company won Endpoints' most promising biopharma start-up and APAC cell and gene therapy start-up awards in 2023.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.immuneel.com"},{"label":"IMAGINE study (ASH 2023 abstract)","url":"https://doi.org/10.1182/blood-2023-181585"}],"tags":[],"related":[],"cancers":["dlbcl"],"sections":["cell-therapy"],"technologies":["car-t","point-of-care-cell-manufacturing"],"targets":["cd19"],"drugs":["varnimcabtagene-autoleucel"],"companies":[],"institutions":["narayana-health"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-manufacturing-cell-therapy","b-global-access"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Bengaluru","country":"IN","companyType":"cell-therapy","website":"https://www.immuneel.com","investors":[],"funding":[]},"route":"/companies/immuneel/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"point-of-care-cell-manufacturing","kind":"technology","name":"Point-of-care and decentralised cell manufacturing","route":"/technologies/point-of-care-cell-manufacturing/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"}],"drug":[{"id":"varnimcabtagene-autoleucel","kind":"drug","name":"Varnimcabtagene autoleucel","route":"/drugs/varnimcabtagene-autoleucel/"}],"institution":[{"id":"narayana-health","kind":"institution","name":"Narayana Health (Mazumdar Shaw Medical Centre)","route":"/institutions/narayana-health/"}],"bottleneck":[{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/"},{"id":"b-global-access","kind":"bottleneck","name":"Most of the world has almost no cancer care","route":"/bottlenecks/b-global-access/"}],"trial":[{"id":"imagine-varnimcabtagene","kind":"trial","name":"IMAGINE (varnimcabtagene autoleucel, Immuneel)","route":"/trials/imagine-varnimcabtagene/"}],"roadmap":[{"id":"global-access-roadmap","kind":"roadmap","name":"Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation","route":"/roadmaps/global-access-roadmap/"}]}}